Ablechild Board Member Featured Speaker Risperdal-Gynecomastia LitigationPrint This Post
Ablechild is pleased to announce that one of its founding board members, Derek Braslow, will be a featured speaker concerning the Risperdal-Gynecomastia litigation at the National Mass Torts Made Perfect Conference in Las Vegas, on October 10, 2014.
Derek has long been an advocate for America’s children and is looking forward to updating some of the nation’s pre-eminent trial attorneys on preparations for the first Risperdal trial, scheduled for November 3, 2014 in Philadelphia.
“Gynecomastia, or the swelling of breast tissue in males,” says Braslow, “can be a devastating consequence of taking Risperdal – especially to young boys going through adolescence.” “Risperdal was not approved for any indication for children or adolescents until October 2006, and thereafter, only for limited indications in that age group – yet many doctors did and continued to prescribe Risperdal off-label for this age group – without appreciating the actual benefits and risks of this psychotropic drug.”
Risperidone is an “atypical antipsychotic,” so called because these drugs are chemically different from and have different side effects than the older antipsychotic medications. While science does not understand the exact mechanism of Risperidone, it is believed that Risperidone affects the way the brain works by blocking the receptors on some of the brain’s nerves, thus altering communication normally done by chemical neurotransmitters.
Johnson & Johnson received FDA approval for Risperdal (their brand name for Risperidone) in 1993 for the treatment of schizophrenia and bipolar disorder in adults only. It was later approved in 2006 for irritability associated with autism in children. Despite not being approved for children and adolescents for any indication prior to 2006, it was promoted “off-label” for a variety of mental health conditions, including attention deficit hyperactivity disorder (ADHD), anxiety, sleep difficulties, depression, Tourette syndrome, stuttering, and obsessive-compulsive disorders.
In addition to causing Gynecomastia, Risperdal carries the risk of other serious side effects as well, including suicidality, heart failure, stroke, uncontrollable movements, diabetes, and neuroleptic malignant syndrome.
Ablechild couldn’t be more pleased that Derek will be the featured speaker on such an important issues affecting so many of today’s youth.
Ablechild Board Member, ADHD, Derek Braslow, Johnson & Johnson, Off-label, Risperdal